早期抗疟药依从性对类风湿关节炎和系统性红斑狼疮患者未来急性医疗利用及费用的影响:一项基于人群的研究
在加拿大不列颠哥伦比亚省1997年至2022年间新发RA/SLE并开始使用抗疟药的患者中,通过倾向评分匹配比较依从者(PDC≥0.90)与非依从者(0<PDC<0.90)。依从者住院率降低11%、住院天数减少21%,且平均住院费用低549.64加元,结果经敏感性分析验证稳健。
要点
- 早期抗疟药高依从性(PDC≥0.90)与RA/SLE患者住院风险降低11%相关。
- 依从者住院天数减少21%,平均住院费用降低549.64加元。
- 该关联在伪造检验和敏感性分析中保持稳健,提示临床应关注早期依从性。
核心结论
- 在RA和SLE患者中,抗疟药依从性与较低的住院风险(降低11%)、住院天数(减少21%)及住院费用(低549.64加元)相关。
研究设计与样本
- 基于加拿大不列颠哥伦比亚省行政数据库的人群队列研究,纳入1997年1月至2022年3月新发RA/SLE并新使用抗疟药且随访至少1年的患者。
- 依从者(PDC≥0.90)按倾向评分匹配最多2名非依从者(0<PDC<0.90),最终匹配8768例依从者和16479例非依从者。
- 采用准泊松和线性模型(稳健标准误)评估依从性对次年住院、住院天数及费用的影响,并进行伪造检验和敏感性分析。
主要发现
- 调整后住院率比(依从者 vs 非依从者)为0.89(95%CI 0.84-0.94),住院天数率比为0.79(95%CI 0.71-0.88)。
- 调整后平均住院费用差异为-549.64加元(95%CI -896.05至-203.22,P<0.01),依从者费用更低。
- 伪造检验和敏感性分析证实结果对健康依从者效应和未测量混杂因素稳健。
关键数值与推荐
- 抗疟药依从定义为 proportion of days covered(PDC)≥0.90,非依从定义为0<PDC<0.90。
临床怎么用
- 对RA和SLE患者启动抗疟药治疗时,应评估并促进早期依从性(PDC≥0.90),以可能降低未来住院风险和费用。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between early antimalarial adherence and future acute care utilization and cost in a population-based cohort of incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). METHODS: All patients with incident RA/SLE and new antimalarial use in British Columbia, Canada, between January 1997 and March 2022 with at least one year of follow-up were identified using provincial administrative databases. Each antimalarial adherent patient (proportion of days covered [PDC] ≥ 0.90) was propensity score (PS) matched up to two antimalarial nonadherent patients (0 < PDC < 0.90). The outcomes hospital admissions, hospitalized days, and hospitalization cost were assessed in the following year. We estimated the impact of early antimalarial adherence on these outcomes, accounting for potential confounders, using quasi-Poisson and linear models with robust SEs. We conducted falsification tests and sensitivity analyses to examine robustness to healthy adherer effect and unmeasured confounders. RESULTS: We identified 8,768 antimalarial adherent and 16,479 antimalarial nonadherent PS-matched individuals with RA/SLE. The adjusted rate ratios of hospital admissions and hospitalized days obtained for antimalarial adherent versus nonadherent patients were 0.89 (95% confidence interval [CI] 0.84-0.94) and 0.79 (95% CI 0.71-0.88), respectively. The adjusted average hospitalization costs were lower (estimate: CAD -$549.64, 95% CI -$896.05 to -$203.22, P < 0.01) for antimalarial adherent patients than nonadherent patients. Falsification tests and sensitivity analyses confirmed the robustness of the results. CONCLUSION: Adherence to antimalarials in patients with RA and SLE was associated with a lower risk of hospital admission (11% reduction) and hospitalized days (21% reduction) and lower hospitalization costs (CAD $549.64 lower) compared to nonadherence.
引用
- Hoque MR, Lacaille D, Aviña-Zubieta JA, et al. Impact of Early Antimalarial Adherence on Future Acute Care Utilization and Cost Among Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study. Arthritis Rheumatol. 2026. PMID: 41657297. doi:10.1002/art.70071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。